By
Jin Kim
November 16, 2026
•
5
min read

One in six people worldwide face infertility, yet reproductive health has seen too little progress for too long. Granata Bio is working to change that by expanding treatment choices and access for patients on the path to parenthood, and its pivotal Phase III GRACE study is an important step forward.
Behind every pivotal study is a constant flow of data that must be accurate, connected, and ready for review. At Miracle, we're proud to partner with Granata Bio, a biotechnology company advancing innovative reproductive health solutions, to support clinical data oversight and study execution for GRACE.
GRACE is evaluating the safety and efficacy of investigational Granata Bio Human Menopausal Gonadotropin (GB-hMG) in women undergoing in vitro fertilization (IVF). The study follows participants through ovarian stimulation, embryo transfer, and pregnancy outcomes, requiring close coordination of clinical, laboratory, and operational data across multiple stages of treatment.
In October 2026, Granata Bio announced the completion of screening, with more than 750 women screened across 15 participating fertility clinics.
As GRACE advances through treatment, embryo transfer, and pregnancy follow-up, the team remains focused on protocol adherence, data quality, and overall study execution.
Miracle supports that work by bringing data from multiple clinical systems into one platform, providing continuously updated study metrics, automated data quality oversight workflows, and flexible analytics that Granata Bio's own team can configure to meet its needs.
Pivotal Phase III studies require tight coordination across sites, vendors, and stakeholders. In fertility studies in particular, timing, enrollment forecasting, safety monitoring, and protocol adherence are critical.
For the GRACE study, key data streams are distributed across several systems:
Answering operational questions often required gathering information from multiple sources, reconciling differences, and manually compiling reports.
During enrollment, the team needed to oversee screening activity, site performance, and recruitment projections. As participants progressed through treatment, data quality oversight became extremely relevant and important.
Granata Bio needed more than a consolidated overview of its data. It needed a flexible way to turn that data into useful study metrics and workflows without constantly relying on manually maintained trackers or new vendor reports.
Miracle integrates Granata Bio's clinical data into a centralized platform, giving the monitoring team remote access to study-, site-, and subject-level information.
During the enrollment phase, Miracle helped Granata Bio track screening and randomization activity, monitor site performance, and explore enrollment projections under different scenarios.
The platform also helped identify data quality issues early.

As the study progressed, Granata Bio expanded its use of Miracle beyond recruitment metrics.
The dashboards provide a comprehensive view of critical study metrics, enabling proactive identification of potential safety signals, protocol deviations, data inconsistencies, and data quality issues. By supporting the review of data timeliness and completeness, they enhance data management and cleaning efforts. Moreover, they facilitate centralized monitoring through the early detection of site performance issues, improve oversight of study progress, and enable efficient remote site monitoring across the trial.
This gives clinical operations, scientific, and executive teams a broader view of study progress, without having to assemble separate reports for every question.
Beyond monitoring study progress, Granata Bio uses Miracle to support data quality oversight.
Tracking source data verification (SDV), data management review, and page status across subjects and visits can be time-consuming, particularly as a pivotal study accumulates more data.
Miracle brings these review indicators together so the team can more easily understand:
Instead of repeatedly checking individual records across systems or compiling status updates manually, the team can use consolidated views to identify incomplete work and prioritize follow-up.
As GRACE moves further into treatment and pregnancy follow-up, maintaining visibility into data review status remains an important part of study oversight.
One of the distinguishing aspects of the partnership is how independently Granata Bio's team uses Miracle.
Rather than relying on Miracle to build every dashboard or report, Granata Bio has used the platform's self-service capabilities to create and refine analytics around its study needs.
Team members can configure visualizations, define metrics, apply filters, and examine trends in the underlying data.
For example, during enrollment, Granata Bio could assess screening-to-randomization timelines and explore recruitment projections based on different assumptions.

As the study progressed, the same flexibility allowed Granata Bio to extend its dashboards into additional areas of clinical and operational oversight.
This approach enables a team that understands its protocol and day-to-day workflows to answer new questions as they arise, without rebuilding its reporting infrastructure each time.
Granata Bio's use of Miracle has evolved alongside GRACE.
Early priorities included monitoring recruitment, evaluating enrollment scenarios, and surfacing inconsistencies in clinical data.
Today, the platform also supports broader review of treatment progress, SDV, and data management activities.
The value is not simply having data from different systems available on one screen. It's having that information organized in a way that allows the team to examine study progress, ensure data quality oversight, and investigate quality issues as the study moves through different phases.

Granata Bio and Miracle first connected more than three years ago, when Miracle was in its earliest stages. Through continued industry relationships, the collaboration came full circle and into a partnership supporting Granata Bio’s pivotal Phase III program.
Today, we're proud to support a team that's not only using connected clinical data for operational visibility but also taking ownership of how it builds and evolves its analytics.
With screening complete, GRACE is progressing through treatment, embryo transfer, and pregnancy follow-up.
As new clinical data becomes available, Miracle will continue supporting Granata Bio's oversight through connected dashboards, quality metrics, and projections.
We're excited to support Granata Bio as it advances GRACE and works toward expanding treatment options for patients pursuing IVF.
To learn more about their study, please visit https://clinicaltrials.gov/study/NCT07216742.
Miracle is the control room for clinical trials. Our platform connects data from clinical systems to automate reporting, streamline operational workflows, and give sponsors visibility into study progress, data quality, and emerging issues.
For more information, visit miracleml.com or contact sales@miracleml.com.
See how Miracle connects your study systems, eliminates manual trackers, and gives your team real-time visibility into study risks.
Go live in days, not weeks.